αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell–related features
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 2, 2015
- Accepted in final form March 23, 2015
- First Published May 7, 2015.
Author Disclosures
- Kathrin Held, PhD,
- Latika Bhonsle-Deeng, PhD,
- Katherina Siewert, PhD,
- Wakiro Sato, MD,
- Eduardo Beltrán, PhD,
- Stephan Schmidt, MD,
- Geraldine Rühl, MSc,
- Judy K.M. Ng, PhD,
- Peter Engerer, MSc,
- Markus Moser, PhD,
- Wolfgang E.F. Klinkert, PhD,
- Holger Babbe, PhD,
- Thomas Misgeld, MD,
- Hartmut Wekerle, MD,
- David-Axel Laplaud, MD,
- Reinhard Hohlfeld, MD and
- Klaus Dornmair, PhD
- Kathrin Held, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Latika Bhonsle-Deeng, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Katherina Siewert, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Wakiro Sato, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) grant support from Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eduardo Beltrán, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stephan Schmidt, MD,
(1) Novartis; (2) Merck Serono; (3) Bayer Vital; (4) Biogen Idec; (5) Genzyme; (6) TEVA
NONE
(1) Novartis; (2) Merck Serono; (3) Bayer Vital; (4) Biogen Idec; (5) Genzyme; (6) TEVA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Bayer Vital. Grant for a clinical study entitled: Aerobic endurance exercise in mildly disabled MS patients
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Geraldine Rühl, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Judy K.M. Ng, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peter Engerer, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Markus Moser, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Wolfgang E.F. Klinkert, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Holger Babbe, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Janssen Research & Development LLC, Staff Scientist, 6 years
NONE
NONE
NONE
NONE
Janssen Research & Development LLC
NONE
Wife is employee at the Coriell Institute for Medical Research, Camden, NJ
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas Misgeld, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
2011-2015 Project grant, RTG 1373, DFG ? Mitochondria-imaging 2013-2017 AI, CIPSM Cluster of Excellence, DFG ? Optogenetics in zebrafish retina 2013-2017 PI, SyNergy Cluster of Excellence, DFG ?Mitochondrial proteomics 2014-2015 GIF proposal (w. A. Yaron, Weizmann I.) ? Engulfment in Wallerian degeneration 2014-2018Project grant, CRC 870, DFG ? Interneuron polarization in vivo 2014-2019 Consolidator grant, ERC ? In vivo imaging of axon loss
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hartmut Wekerle, MD,
Myelin Repair Foundation, Sarasota, CA Novimmune, Geneva, Switzerland
NONE
NONE
Annals of Neurology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
KKNMS, German Ministry of Science
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David-Axel Laplaud, MD,
(1) from Biogen-Idec, (2) TEVA Pharma, (3) Novartis (4) Genzyme
NONE
(1) Biogen-Idec, (2) Novartis (3) Genzyme
(1)La Presse M?dicale, editor, 2015 (2) SEP & Neuroscience, co-editor, 2012 until now
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Biogen-Idec, (2)Novartis
NONE
(1) LFSEP
(1) Fondation ARSEP
NONE
NONE
NONE
NONE
NONE
NONE
- Reinhard Hohlfeld, MD and
Served on Scientific Advisory boards for Novartis; Biogen- Idec; Bayer-Schering; Merck-Serono; Sanofi-Aventis; Teva; Served on data safety monitoring boards for Novartis; Merck Serono (since 2007); CSL Behring
NONE
Received funding for trips from Novartis; Biogen-Idec; Bayer-Schering; Merck-Serono; Sanofi- Aventis; Teva; Genzyme
Serve as editorial board member of Neurology (currently); Brain; Clinical and Experimental Immunology; Deutsche Medizinische Wochenschrift; Expert Opinion on Biological Therapy; Journal of Neuroimmunology; Multiple Sclerosis; Nervenarzt; Practical Neurology; Seminars in Immunopathology; Therapeutic Advances in Neurological Disorders
NONE
NONE
NONE
Receive consulting fees from Novartis; Biogen-Idec; Bayer- Schering; Merck-Serono; Sanofi-Aventis; Teva; Genzyme
NONE
NONE
NONE
Received grant support from Novartis (2008 to present); Biogen-Idec (2005-2009); Bayer-Schering (2001-2006); Teva (1999-2007)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Klaus Dornmair, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Deutsche Forschungsgemeinschaft (Munich Cluster for Systems Neurology (EXC 1010 SyNergy), (2) Deutsche Forschungsgemeinschaft CRC-TR-128-A5, -128-A1, and -128-B8),
NONE
(1) Deutsche Multiple Sklerose Gesellschaft (DMSG), (2) Fondation pour l?Aide ? la Recherche sur la Scl?rose en Plaques (ARSEP),
NONE
NONE
NONE
NONE
NONE
NONE
- From the Institute of Clinical Neuroimmunology (K.H., L.B.-D., K.S., W.S., E.B., G.R., J.K.M.N., R.H., K.D.), Ludwig-Maximilians University, Munich, Germany; Neurologische Gemeinschaftspraxis (S.S.), Gesundheitszentrum St. Johannes Hospital, Bonn, Germany; Institute of Neuronal Cell Biology (P.E., T.M.), TU Munich, Munich, Germany; Department for Molecular Medicine (M.M.), Max-Planck-Institute of Biochemistry, Martinsried, Germany; Department for Neuroimmunology (W.E.F.K., H.W.), Max-Planck-Institute of Neurobiology, Martinsried, Germany; Department of Genetics (H.B.), Harvard Medical School, Boston, MA; Munich Cluster for Systems Neurology (SyNergy) (T.M., H.W., R.H., K.D.), Munich, Germany; German Center for Neurodegenerative Diseases (DZNE) and Center for Integrated Protein Science (CIPSM) (T.M.), Munich, Germany; and INSERM, UMR 1064 (D.A.L.), Nantes, France.
- Correspondence to Dr. Dornmair: Klaus.Dornmair{at}med.uni-muenchen.de
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.